Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C21H21FN2O4S |
| Molecular Weight | 416.466 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C1CCC2=C(C1)C3=C(C=CC=C3)N2CC(O)=O)S(=O)(=O)C4=CC=C(F)C=C4
InChI
InChIKey=CANCTKXGRVNXFP-UHFFFAOYSA-N
InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
| Molecular Formula | C21H21FN2O4S |
| Molecular Weight | 416.466 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17328802Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16418339
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17328802
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16418339
TM30089 is a slective CRTH2 antagonist. TM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22224640 |
3.6 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. | 2012 |
|
| Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. | 2007-02-28 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17328802
Mice: mice were treated twice daily with TM30089 (5 mg/kg orally)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22442685
1 uM of TM30089 inhibited chemotactic activation of human eosinophils, measured in eosinophil shape change assays.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:40:59 GMT 2025
by
admin
on
Wed Apr 02 10:40:59 GMT 2025
|
| Record UNII |
F449K9EB2G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00722396
Created by
admin on Wed Apr 02 10:40:59 GMT 2025 , Edited by admin on Wed Apr 02 10:40:59 GMT 2025
|
PRIMARY | |||
|
11384493
Created by
admin on Wed Apr 02 10:40:59 GMT 2025 , Edited by admin on Wed Apr 02 10:40:59 GMT 2025
|
PRIMARY | |||
|
627865-18-3
Created by
admin on Wed Apr 02 10:40:59 GMT 2025 , Edited by admin on Wed Apr 02 10:40:59 GMT 2025
|
PRIMARY | |||
|
F449K9EB2G
Created by
admin on Wed Apr 02 10:40:59 GMT 2025 , Edited by admin on Wed Apr 02 10:40:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|